In the event of failure after initial or repeated pituitary surgery, second-line treatments of regrowing adenomas include adjuvant radiotherapy, stereotactic radiosurgery, selective somatostatin analogues (pasireotide), dopamine agonists (cabergoline) or sodium valproate [1–3], and, finally, EGFR kinase tyrosine inhibitors (gefitinib) [3, 4] and an antiangiogenic agent, bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor VEGF [5]. Here, VEGFA is linked to adenoma.